Hassan R, et al. - Authors assessed 53 patients (median age of 67 years) to evaluate the effectiveness and safety of avelumab (10 mg/kg, every 2 weeks until disease progression or unacceptable toxic effects) in those with previously treated mesothelioma in this phase 1b open-label study. They observed durable responses in candidates with anti-programmed cell death ligand 1 (PD-L1)–positive tumors and PD-L1–negative tumors, based on a 5% or greater PD-L1 cutoff. They also noted a 58% disease control rate with median progression-free survival (PFS) of 4.1 months and the 12-month PFS rate of 17.4%. A median overall survival (OS) of 10.7 months and the median 12-month OS rate of 43.8% were also found with no treatment-related deaths. An acceptable safety profile was seen with avelumab, with durable antitumor activity and disease control.